Andrew Koustenis

Andrew is an experienced oncology professional with over 30 years of proven results across the entire spectrum of pharmaceutical drug development including clinical, regulatory, and marketing functions. Andrew graduated with a B.S. in Pharmacy from the University of Maryland. He then gained clinical research experience at the National Cancer Institute and Penn State Medical Center. During a successful career at Eli Lilly, he excelled in positions with medical information, market research, regulatory and medical affairs, as well as clinical development. After retiring from Eli Lilly, he initiated a successful second career in a leadership role at Verastem Oncology followed by a career at OncXerna Therapeutics. He has experience in multiple diverse areas and exposure to compounds at all phases of development from preclinical to late-stage clinical development.